Summary of Key Information:
Reporting Period (Quarter/Year): Not Applicable
Nature of Filing / Announcement: Outcome of Board Meeting - Preferential Issue Approval
Audit Opinion:
Not Specified
Key Financial Highlights:
Not Specified
Corporate Actions:
The Board approved a preferential issue of up to 82,10,786 fully paid-up equity shares of face value of Rs. 1 each at an issue price of Rs. 408 per equity share (including securities premium of Rs. 407), aggregating Rs. 335,00,00,688.
Investor Allocation Details:
- Pharmaceutical Business Group (India) Limited (Promoter group): 61,27,453 shares (Rs. 250,00,00,824)
- Yusuf Khwaja Hamied (Non-promoter): 2,45,100 shares (Rs. 10,00,00,800)
- Special Situation India Fund (Non-promoter): 4,59,558 shares (Rs. 18,74,99,664)
- India Special Assets Fund III (Non-promoter): 6,83,823 shares (Rs. 27,89,99,784)
- ISAF III Onshore Fund (Non-promoter): 6,94,852 shares (Rs. 28,34,99,616)
Total non-promoter allocation: 20,83,333 shares (Rs. 85,00,00,000)
Other Significant Information:
The company's registered office and factory is located at 69/C GIDC Industrial Estate, Vapi – 396 195, Dist. Valsad, Gujarat, India.